Wall Street brokers expect BeiGene, Ltd. (NASDAQ:BGNE - Get Rating) will post ($4.38) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts provided earnings estimates for BeiGene, with the lowest EPS estimate of $4.45 and the highest estimate of $4.30. BeiGene reported earnings of ($5.23) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 16.3%. The company is expected to announce its next results on Monday, January 1.
According to Zacks, analysts expect BeiGene to report annual earnings of $15.13 per share for the current fiscal year, with EPS estimates ranging from $17.44 to $12.37. For next year, analysts expect the company to report earnings of ($11.00) per share, with EPS estimates ranging from ($16.87) to ($7.49). Zacks earnings per share averages are an average average based on a survey of sell-side analysts who provide coverage for BeiGene.
BeiGene (NASDAQ:BGNE - Get Rating) last reported quarterly earnings data on Thursday, May 5. The company reported ($4.24) earnings per share for the quarter, missing analyst consensus estimates of ($4.12) by ($0.12). BeiGene had a negative net margin of 218.25% and a negative return on equity of 40.10%. The company posted revenue of $306.60 million in the quarter, compared to $300.41 million expected by analysts. The company’s quarterly revenue was down 49.4% year over year.
BGNE has been the subject of several analyst reports. SVB Leerink downgraded BeiGene from an ‘outperforming’ rating to a ‘market performing’ rating and reduced its price target for the stock from $300.00 to $177.00 in a Thursday, March 17 report . Morgan Stanley raised its price target on BeiGene from $330.00 to $338.00 and gave the stock an “overweight” rating in a Tuesday, April 12 report. StockNews.com launched coverage on BeiGene in a report on Thursday, March 31. They put a “sell” mark on the stock. Zacks Investment Research downgraded BeiGene from a “buy” rating to a “hold” rating in a Tuesday, May 10 report. Finally, Deutsche Bank Aktiengesellschaft began covering BeiGene in a research report on Monday, February 7. They set a “buy” rating for the company. One research analyst rated the stock with a sell rating, two assigned a hold rating and five assigned the company a buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $281.25.
Separately, COO Xiaobin Wu sold 6,725 shares of the company in a trade dated Thursday, May 5. The stock was sold at an average price of $164.35, for a total transaction of $1,105,253.75. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via this hyperlink. 8.90% of the shares are currently held by insiders of the company.
Several hedge funds and other institutional investors have recently increased or reduced their holdings in BGNE. Marshall Wace North America LP acquired a new position in BeiGene in Q1 worth approximately $76,000. Amundi Pioneer Asset Management Inc. increased its position in BeiGene shares by 9.7% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 17,001 shares of the company worth $2,244,000 after buying an additional 1,500 shares last quarter. Morgan Stanley increased its position in BeiGene shares by 205.8% during the second quarter. Morgan Stanley now owns 114,502 shares of the company worth $39,296,000 after buying an additional 77,060 shares last quarter. American Century Companies Inc. increased its position in BeiGene shares by 6.7% during the third quarter. American Century Companies Inc. now owns 3,204 shares of the company worth $1,163,000 after purchasing an additional 202 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in BeiGene shares by 5.0% during the third quarter. Geode Capital Management LLC now owns 206,716 shares of the company worth $74,530,000 after purchasing an additional 9,899 shares last quarter.
Shares of NASDAQ BGNE traded at $3.10 during Friday trading, hitting $141.91. 158,580 shares of the company were traded, against an average volume of 307,634. BeiGene has a 12-month low of $118.18 and a 12-month high of $426.56. The company has a debt ratio of 0.03, a quick ratio of 4.87 and a current ratio of 5.05. The company has a fifty-day moving average price of $161.57 and a 200-day moving average price of $217.14. The company has a market capitalization of $14.58 billion, a PE ratio of -7.06 and a beta of 0.87.
BeiGene Company Profile (Get an assessment)
BeiGene, Ltd. discovers, develops, manufactures and markets drugs for the treatment of cancer in the People’s Republic of China, the United States and abroad. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat classic R/R Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukaemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric Castleman’s disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer and non-small cell lung cancer (NSCLC).
Get a Free Copy of Zacks Research Report on BeiGene (BGNE)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in BeiGene right now?
Before you consider BeiGene, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and BeiGene wasn’t on the list.
Although BeiGene currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here